| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603122 | 合富中国 | 15.77 | 9.97% | 126.77万 | 17.81亿 | | 002788 | 鹭燕医药 | 9.61 | 3.00% | 44.22万 | 4.18亿 | | 301408 | 华人健康 | 14.23 | 2.74% | 15.51万 | 2.17亿 | | 603939 | 益丰药房 | 23.68 | 1.89% | 8.81万 | 2.07亿 | | 000950 | 重药控股 | 5.52 | 1.66% | 36.22万 | 2.00亿 | | 603233 | 大参林 | 18.29 | 1.50% | 5.92万 | 1.08亿 | | 600538 | 国发股份 | 5.76 | 1.41% | 12.89万 | 7395.89万 | | 000411 | 英特集团 | 11.58 | 1.40% | 7.16万 | 8237.43万 | | 603368 | 柳药集团 | 4 19. ...

前期的"跑马圈地"，让A股连锁药店企业普遍商誉偏高。东方财富Choice数据显示，截至今年三季度 末，A股6家连锁药店企业合计商誉达207.78亿元，其中老百姓账上商誉最高，为57.63亿元。此外，老 百姓、健之佳账上商誉占流动资产的比例超过50%。 商誉的积累源于连锁药店行业特有的发展模式。过去数年，连锁药店企业通过频繁并购实现快速扩张。 如今，连锁药店已不再规模化扩张，多家企业开始出现直营门店数量下降的现象。门店数量的下降，标 志着连锁药店行业进入深度调整期，如何平衡规模效应与经营质量将成为行业核心议题。 平均商誉达34.63亿元 东方财富Choice数据显示，截至三季度末，A股6家连锁药店企业账上均存在高额商誉，合计商誉值达 207.78亿元，平均值为34.63亿元。其中，老百姓账上商誉最高。截至三季度末，老百姓账面商誉排名首 位，余额达57.63亿元；益丰药房次之，为47.72亿元；大参林排名第三，商誉余额为35.22亿元。 从商誉占流动资产的比例看，老百姓同样位于榜首，为65.28%；健之佳也超过50%，为58.7%。 将时间拉长来看，连锁药店企业商誉高企的现象已存在多年。2022年，老百姓账上商誉 ...

Group 1 - MSCI announced the results of its November index review, which includes the addition of 17 new A-shares and the removal of 16 A-shares [2][3] - The newly added A-shares include companies such as Qianli Technology, Dongyangguang, and Changchuan Technology, while the removed A-shares include companies like Zhongzhi Co., Bertley, and Dong'a Ejiao [1][3] - The adjustments will take effect after the market closes on November 24 [2] Group 2 - In addition to A-shares, MSCI also included 9 new Hong Kong stocks in its indices, such as Zijin Mining International and GF Securities, while removing 4 Hong Kong stocks [3][4] - The largest new additions to the MSCI Global Standard Index include companies like CoreWeave, Nebius Group, and Insmed, indicating a focus on sectors like cloud services and biopharmaceuticals [4] - MSCI conducts four routine adjustments to its indices each year, with the November review being one of the two major semi-annual assessments [5]

前期的"跑马圈地"，让A股连锁药店企业普遍商誉偏高。东方财富Choice数据显示，截至三季度末，A股6家连锁药 店企业合计商誉达到207.78亿元，其中老百姓（603883）账上商誉最高，为57.63亿元。此外，老百姓、健之佳账上 商誉占流动资产的比例超过50%。商誉的积累源于连锁药店行业特有的发展模式。在过去数年里，连锁药店企业通 过频繁并购实现快速扩张。如今，连锁药店已不再规模化扩张，多家企业开始出现直营门店数量下降的现象。门店 数量的下降，标志着连锁药店行业进入深度调整期，如何平衡规模效应与经营质量将成为行业核心议题。 | 证券代码 | 证券名称 | 商管 ممب | 所属行业名称 [报告类型]合并报表 [行业类别]3级 | | 流困资产合计 [报告类型]合并报表 | | --- | --- | --- | --- | --- | --- | | | | | [报告期今年三季 | 行业标准 申万行业 ... | [报告期]今年三季 | | | | | [单位 亿元 | [截止日期]最新(202 ... ▼ | [单位]亿元 | | 603883.SH | 老百姓 | > | 57.6333 线下药店 | ...

Core Insights - MSCI announced the results of its November index review, which includes the addition of 17 new stocks to the MSCI China A-share index and the removal of 16 stocks. The changes will take effect after the market closes on November 24, 2025 [1][6]. Summary of Adjustments - **Newly Added Stocks**: The list includes stocks such as Qianli Technology (601777.SH), Dongyangguang (600673.SH), and Changchuan Technology (300604.SZ) among others [4]. - **Removed Stocks**: Stocks such as Zhongzhi Co., Ltd. (600038.SH), Bertli (603596.SH), and Dong'e Ejiao (000423.SZ) are among those being removed from the index [4]. - **Hong Kong Stocks**: In addition to A-share stocks, the MSCI China index also added nine Hong Kong stocks including Zijin Mining International and GF Securities, while removing four stocks such as Beijing Enterprises Water Group [4]. Global Index Adjustments - **Global Standard Index Changes**: MSCI's global standard index (ACWI) added 69 stocks and removed 64 stocks, with notable additions including CoreWeave, Nebius Group, and Insmed [5]. - **Emerging Markets Index**: The largest new additions to the MSCI Emerging Markets Index include Barito Renewables Energy from Indonesia, Zijin Mining International, and GF Securities [5]. Adjustment Frequency and Impact - MSCI conducts four routine adjustments annually, with the May and November adjustments typically being more significant. Adjustments are based on objective quantitative metrics such as market capitalization and liquidity [6].

北京时间11月6日早间，全球知名指数公司MSCI宣布了2025年11月份指数审核结果。此次调整将于11月24日收盘后正式生效。 | 新增 | 剔除 | | --- | --- | | 中国黄金国际 | 中直股份 | | 中国有色矿业 | 北控水务集团 | | 千里科技 | 伯特利 | | 东风集团股份 | 中国光大银行 | | 赣锋锂业 | 华润医药 | | 广发证券 | 东阿阿胶 | | 东阳光 | 广电运通 | | 长川科技 | 海格通信 | | 华虹公司 | 海澜之家 | | --- | --- | | 兴业银锡 | 华兰生物 | | 金力永磁 | 凤凰传媒 | | 金发科技 | 梅花生物 | | 恺英网络 | 南京证券 | | 荣昌生物 | 纳恩达 | | 上海电气 | 欧派家居 | | 协创数据 | 西南证券 | | 生益电子 | 中国民航信息网络 | | 英维克 | 建发股份 | | 长盈精密 | 益丰药房 | | 江波龙 | 金龙鱼 | | 中材科技 | | 具体来看，MSCI全球标准指数新纳入69只股票，剔除64只股票。按公司总市值计算，纳入MSCI全球指数的三只最大证券分别是CoreWeav ...

Group 1: 华勤技术 (603296.SH) - The company achieved a revenue of 128.82 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 70% [7] - The net profit attributable to shareholders reached 3.099 billion yuan, up 51% year-on-year [7] - The company’s gross margin improved to 8.17% in Q3 2025, an increase of 1.04 percentage points from Q2 2025 [7] - The company is expanding its global manufacturing layout, achieving large-scale shipments in India and Vietnam [8] - The multi-category business strategy is expected to drive significant performance growth, with projected net profits of 4.15 billion yuan, 5.15 billion yuan, and 6.17 billion yuan from 2025 to 2027 [8] Group 2: 汉朔科技 (301275.SZ) - The company reported a revenue of 2.809 billion yuan in the first three quarters of 2025, a decrease of 11% year-on-year [10] - The net profit attributable to shareholders was 314 million yuan, down 41% year-on-year [10] - The gross margin for Q3 2025 was 35.94%, an increase of 5.23 percentage points from Q2 2025, indicating a recovery in profitability [10] - The company is focusing on digitalization in the retail sector, with a business model centered around electronic price tag systems and SaaS cloud platform services [11] - Projected revenues for 2025 to 2027 are 4.056 billion yuan, 4.787 billion yuan, and 5.747 billion yuan, respectively [11] Group 3: 天山电子 (301379.SZ) - The company achieved a revenue of 1.338 billion yuan in the first three quarters of 2025, a year-on-year increase of 26.48% [12] - The net profit attributable to shareholders was 113 million yuan, up 7.75% year-on-year [12] - The company is strategically investing in the storage sector, aiming to create a complete storage ecosystem [13] - The projected revenues for 2025 to 2027 are 1.978 billion yuan, 2.546 billion yuan, and 2.893 billion yuan, respectively [13] Group 4: 恒瑞医药 (600276.SH) - The company reported a revenue of 23.188 billion yuan in the first three quarters of 2025, representing a 14.85% increase [15] - The net profit attributable to shareholders was 5.751 billion yuan, up 24.50% year-on-year [15] - The company is accelerating its internationalization efforts, with multiple overseas collaborations and licensing agreements [16] - The projected net profits for 2025 to 2027 are 8.8 billion yuan, 10.28 billion yuan, and 12.15 billion yuan, respectively [18] Group 5: 益丰药房 (603939.SH) - The company achieved a revenue of 17.286 billion yuan in the first three quarters of 2025, a slight increase of 0.39% [20] - The net profit attributable to shareholders was 1.225 billion yuan, up 10.27% year-on-year [20] - The company is focusing on non-pharmaceutical innovations, which are expected to drive growth in the future [21] - The company plans to optimize its store network and expand its franchise business, with a total of 14,666 stores as of Q3 2025 [21] Group 6: 中兴通讯 (000063.SZ) - The company reported a revenue of 100.52 billion yuan in the first three quarters of 2025, a year-on-year increase of 11.63% [23] - The net profit attributable to shareholders was 5.32 billion yuan, down 32.7% year-on-year [23] - The company is experiencing pressure in its operator business, but its computing power segment is showing significant growth [24] - The projected net profits for 2025 to 2027 are 7.4 billion yuan, 8.5 billion yuan, and 10 billion yuan, respectively [24] Group 7: 德科立 (688205.SH) - The company achieved a revenue of 6.5 billion yuan in the first three quarters of 2025, a year-on-year increase of 8.6% [26] - The net profit attributable to shareholders was 40 million yuan, down 47.4% year-on-year [26] - The company is focusing on DCI (Data Center Interconnect) products, which are experiencing accelerated growth [27] - The projected net profits for 2025 to 2027 are 70 million yuan, 250 million yuan, and 410 million yuan, respectively [27] Group 8: 北新建材 (000786.SZ) - The company reported a revenue of 19.905 billion yuan in the first three quarters of 2025, a decrease of 2.25% year-on-year [29] - The net profit attributable to shareholders was 2.586 billion yuan, down 17.77% year-on-year [29] - The company is facing challenges in its gypsum board business but is seeing growth in its other segments [30] - The projected net profits for 2025 to 2027 are 3.364 billion yuan, 3.959 billion yuan, and 4.432 billion yuan, respectively [32]

Group 1 - MSCI announced changes to its indices, including the addition of 17 new A-share stocks and the removal of 16 stocks, effective after the market close on November 24, 2025 [1] - The newly added A-share stocks include 千里科技 (601777.SH), 东阳光 (600673.SH), and 长川科技 (300604.SZ), while stocks like 中直股份 (600038.SH) and 海澜之家 (600398.SH) were removed [1] - In addition to A-shares, 9 Hong Kong stocks were added to the MSCI China Index, including 紫金黄金国际 and 广发证券, while 4 stocks were removed [1] Group 2 - MSCI's global standard index (ACWI) added 69 stocks and removed 64, with notable additions including CoreWeave and Nebius Group [2] - The largest new additions to the MSCI Emerging Markets Index include Barito Renewables Energy, 紫金黄金国际, and 广发证券 [2] - MSCI conducts four routine adjustments to its indices annually, with May and November adjustments typically being more significant [2]

Core Insights - MSCI announced the results of its November index review, which includes the addition of 17 new stocks to the MSCI China A-share index and the removal of 16 stocks. The changes will take effect after the market closes on November 24, 2025 [1][4]. Group 1: A-Share Index Adjustments - New additions to the MSCI China A-share index include stocks such as Qianli Technology (601777.SH), Dongyangguang (600673.SH), and Changchuan Technology (300604.SZ) [4]. - Stocks removed from the index include Zhongzhi Co., Ltd. (600038.SH), Berteli (603596.SH), and Dong'a Ejiao (000423.SZ) [4]. Group 2: Hong Kong Stock Adjustments - In addition to A-share stocks, the MSCI China index also added nine Hong Kong stocks, including Zijin Mining International and GF Securities, while removing four stocks such as Beijing Enterprises Water Group [4]. Group 3: Global Index Adjustments - MSCI's global standard index (ACWI) added 69 stocks and removed 64, with notable new additions including CoreWeave, Nebius Group, and Insmed [5]. - The largest new additions to the MSCI Emerging Markets Index include Barito Renewables Energy, Zijin Mining International, and GF Securities [5]. Group 4: Adjustment Frequency and Impact - MSCI conducts four routine adjustments to its indices annually, with the May and November adjustments typically having a larger impact compared to the February and August adjustments [6]. - Adjustments are based on objective quantitative indicators such as market capitalization and liquidity, and historical analysis suggests that the overall market impact of MSCI's routine adjustments is manageable [6].

Market Overview - The pharmaceutical commercial sector declined by 0.5% on November 4, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 11.85, up 10.03% [1] - Renmin Tongtai (600829) at 9.71, up 8.01% [1] - Jianfa Zhixin (301584) at 35.42, up 5.20% [1] - Baiyang Pharmaceutical (301015) saw a significant decline, closing at 25.62, down 6.09% [2] - Other notable decliners included: - Yifeng Pharmacy (603939) at 23.76, down 3.22% [2] - Saili Medical (603716) at 24.78, down 3.17% [2] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 32.34 million yuan from institutional investors, while retail investors saw a net outflow of 41.10 million yuan [2] - The capital flow for key stocks showed: - Renmin Tongtai had a net inflow of 63.04 million yuan from institutional investors [3] - Yifeng Pharmacy experienced a net outflow of 32.44 million yuan from retail investors [3]